好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comparative Effectiveness of Rituximab Versus Ocrelizumab Using Real-world Evidence: A Canadian Propensity-score Matched Observational Study
Multiple Sclerosis
P12 - Poster Session 12 (11:45 AM-12:45 PM)
1-005
To compare the effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis in a real-world setting.

Rituximab is used as an off-label first-line treatment for multiple sclerosis (MS) in British Columbia, Canada. Recent research has suggested that rituximab is not non-inferior to ocrelizumab, despite similar therapeutic mechanisms.

Medical records were manually abstracted for individuals with MS treated with rituximab or ocrelizumab at the University of British Columbia and Prince George MS Clinics in British Columbia between February 2017 and June 2024, inclusive. Individuals with ≥12 months of clinical follow up were matched 1:1 on propensity score based on age, sex, MS duration, disability, prior therapy, income quintile, treatment indication and recent relapse activity. The primary outcomes were annualized relapse rate (ARR) and cumulative hazard of relapses.

In total, 692 individuals treated with rituximab (n=283) or ocrelizumab (n=409) fulfilled inclusion criteria (mean [SD] age; 39.5 [9.91] years; 498 female [72.0%]). After matching, 532 individuals were included in the primary analysis (n=266 pairs). Similar relapse rates were observed (ARR ratio 0.9; 95% CI: 0.5-1.6), with very low ARR in both groups (rituximab 0.04 vs ocrelizumab 0.03). The cumulative hazard of relapses was numerically elevated for rituximab-treated individuals relative to ocrelizumab (hazard ratio, 1.5; 95% CI, 0.9 – 2.8), but the rarity of relapses in both groups precluded conclusive statistical comparison.

Rituximab and ocrelizumab are highly effective therapies for MS with low rates of clinical disease activity among treated individuals. Low occurrence of disease activity resulted in underpowered comparisons. With this limitation, the present study did not suggest clinically meaningful differences in the effectiveness of rituximab and ocrelizumab.
Authors/Disclosures
Nathan Chu, MD
PRESENTER 		Dr. Chu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Jodie Roberts, MD, MSc, FRCPC Dr. Roberts has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Roberts has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. Dr. Roberts has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Novartis. Dr. Roberts has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker with EMD Serono.
David J. Hunt, MD (Vancouver Coastal Health) Dr. Hunt has nothing to disclose.
Donna Kuipers, RN Ms. Kuipers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Ms. Kuipers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Ms. Kuipers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Ms. Kuipers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sentrex. Ms. Kuipers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apotex.
Jomana Morkous, Research Assistant Ms. Morkous has nothing to disclose.
Kyra West Ms. West has nothing to disclose.
Ana-Luiza Sayao, MD (St. Paul's Hospital) Dr. Sayao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Sayao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serono. Dr. Sayao has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Sayao has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Sayao has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Serono. Dr. Sayao has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
Robert L. Carruthers, MD Dr. Carruthers has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Carruthers has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche and Genentech. The institution of Dr. Carruthers has received research support from Roche and Genentech .
Anthony Traboulsee, MD (University of British Columbia) Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Traboulsee has received research support from Roche. The institution of Dr. Traboulsee has received research support from Consortium of MS Centers. The institution of Dr. Traboulsee has received research support from MS Canada. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Workshop Chair with Consortium of MS Centers.
Virginia A. Devonshire, MD (UBC Hospital S126) Dr. Devonshire has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck- Serono. Dr. Devonshire has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Devonshire has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen . Dr. Devonshire has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for novartis. Dr. Devonshire has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for roche. Dr. Devonshire has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for biogen .
Izanne Roos Izanne Roos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Izanne Roos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Izanne Roos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Izanne Roos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Izanne Roos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Izanne Roos has received research support from MSIF-ARSEP. Izanne Roos has received research support from Melbourne Research Scholarship. Izanne Roos has received personal compensation in the range of $0-$499 for serving as a travel support with Merck. Izanne Roos has received personal compensation in the range of $0-$499 for serving as a travel support with Roche.
Tomas Kalincik Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving as a Consultant for National Health and Medical Research Council. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MS Research Australia. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for WebMD Global. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for BioCSL. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. The institution of Tomas Kalincik has received research support from Biogen. The institution of Tomas Kalincik has received research support from Novartis. The institution of Tomas Kalincik has received research support from Genzyme. The institution of Tomas Kalincik has received research support from Roche. The institution of Tomas Kalincik has received research support from Celgene. The institution of Tomas Kalincik has received research support from Merck. The institution of Tomas Kalincik has received research support from MSBase Foundation. The institution of Tomas Kalincik has received research support from ARSEP and EDMUS Foundations. The institution of Tomas Kalincik has received research support from MS Research Australia. The institution of Tomas Kalincik has received research support from National Health and Medical Research Council. The institution of Tomas Kalincik has received research support from Australian Research Council. The institution of Tomas Kalincik has received research support from MS Society. The institution of Tomas Kalincik has received research support from Trish Foundation. Tomas Kalincik has a non-compensated relationship as a scientific leadership group chair with MSBase Foundation that is relevant to AAN interests or activities.
Alice J. Schabas, MD Dr. Schabas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Schabas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Schabas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Schabas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen.